ATE175118T1 - Gezielte immunostimulierung mit bispezifischen stoffen - Google Patents

Gezielte immunostimulierung mit bispezifischen stoffen

Info

Publication number
ATE175118T1
ATE175118T1 AT91919595T AT91919595T ATE175118T1 AT E175118 T1 ATE175118 T1 AT E175118T1 AT 91919595 T AT91919595 T AT 91919595T AT 91919595 T AT91919595 T AT 91919595T AT E175118 T1 ATE175118 T1 AT E175118T1
Authority
AT
Austria
Prior art keywords
antigen
receptor
bispecific
substances
immunostimulation
Prior art date
Application number
AT91919595T
Other languages
English (en)
Inventor
Jean Loup Romet-Lemonne
Michael W Fanger
Original Assignee
Medarex Inc
Romet Lemonne Jean Loup
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24373308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE175118(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medarex Inc, Romet Lemonne Jean Loup filed Critical Medarex Inc
Application granted granted Critical
Publication of ATE175118T1 publication Critical patent/ATE175118T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
AT91919595T 1990-10-05 1991-10-04 Gezielte immunostimulierung mit bispezifischen stoffen ATE175118T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59308390A 1990-10-05 1990-10-05

Publications (1)

Publication Number Publication Date
ATE175118T1 true ATE175118T1 (de) 1999-01-15

Family

ID=24373308

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91919595T ATE175118T1 (de) 1990-10-05 1991-10-04 Gezielte immunostimulierung mit bispezifischen stoffen

Country Status (10)

Country Link
EP (1) EP0553244B8 (de)
JP (1) JP3583420B2 (de)
AT (1) ATE175118T1 (de)
AU (1) AU667460B2 (de)
CA (1) CA2093022C (de)
DE (1) DE69130709T3 (de)
DK (1) DK0553244T4 (de)
ES (1) ES2129029T5 (de)
GR (1) GR3029830T3 (de)
WO (1) WO1992005793A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354738B2 (en) 2005-05-05 2013-01-15 Round Rock Research, Llc Structures including passivated germanium

Families Citing this family (259)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018031A (en) * 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
AU5322494A (en) * 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
PT749325E (pt) * 1994-03-07 2002-11-29 Medarex Inc Mpleculas biespecificas possuindo utilidades clinicas
US6111166A (en) * 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6365161B1 (en) 1995-06-07 2002-04-02 Medarex, Inc. Therapeutic compounds comprised of anti-FC receptor binding agents
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
CA2232344C (en) 1995-10-20 2005-04-05 University Of Nebraska Board Of Regents Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
EP0808897A1 (de) * 1996-05-21 1997-11-26 I.D.M. Immuno-Designed Molecules Antigenpräsentierende Zellen, ein Verfahren zur deren Herstellung und deren Verwendung als zelluläre Impfstoffen
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
ATE218143T1 (de) 1996-09-03 2002-06-15 Gsf Forschungszentrum Umwelt Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität
AUPO280796A0 (en) * 1996-10-07 1996-10-31 Austin Research Institute, The Methods of activating or enhancing FC receptors
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6682928B2 (en) 1997-12-02 2004-01-27 Medarex, Inc. Cells expressing anti-Fc receptor binding components
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1093457B8 (de) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
AU773561B2 (en) * 1998-03-30 2004-05-27 I.D.M. Immuno-Designed Molecules Stimulated monocyte derived cells, their preparation and uses
US20020168347A1 (en) * 1998-04-09 2002-11-14 Jacques Bartholeyns Use of monocytes derived cells, antigens and antibodies for optimal induction of immunotherapeutic efficiency
DE19835633C1 (de) * 1998-08-06 1999-08-26 Gsf Forschungszentrum Umwelt Induktion einer Tumorimmunität durch Redirektion von Tumorzellen gegen Antigen-präsentierende Zellen
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
EP1173485A1 (de) * 1999-05-03 2002-01-23 Medarex, Inc. Menschlische antikörper gegen staphylococcus aureus
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
EP1274720A4 (de) 2000-04-12 2004-08-18 Human Genome Sciences Inc Albumin enthaltende fusionsproteine
IL152748A0 (en) 2000-05-11 2003-06-24 Altarex Inc Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
EP2431054A3 (de) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Menschlicher Tumornekrosefaktor Delta und Ypsilon
AU6842701A (en) 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
EP2338512A1 (de) 2000-11-28 2011-06-29 MedImmune, LLC Verfahren zur Verabreichung/Dosierung von Anti-RSV-Antikörpern zur Prophylaxe und Behandlung
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20030059834A1 (en) * 2001-02-01 2003-03-27 Chang Nancy T. Methods to generate and identify monoclonal antibodies to a large number of human antigens
EP1683865A3 (de) 2001-02-02 2006-10-25 Eli Lilly & Company Säugerproteine und insbesondere CD200
JP2005503116A (ja) 2001-02-09 2005-02-03 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド ヒトｇタンパク質ケモカインレセプター（ｃｃｒ５）ｈｄｇｎｒ１０
ATE470676T1 (de) 2001-04-13 2010-06-15 Human Genome Sciences Inc Anti-vegf-2 antikörper
WO2002085405A2 (en) 2001-04-24 2002-10-31 Merck Patent Gmbh COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
US6867189B2 (en) 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
DE60326931D1 (de) 2002-01-08 2009-05-14 Novartis Vaccines & Diagnostic In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
IL162844A0 (en) * 2002-01-18 2005-11-20 Inovio As Use of an expression vector for preparing pharmaceutical compositions
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1499352A4 (de) 2002-04-12 2006-10-11 Medimmune Inc Rekombinante anti-interleukin-9-antikörper
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
JP4459810B2 (ja) 2002-08-14 2010-04-28 マクロジェニクス，インコーポレーテッド ＦｃγＲＩＩＢ特異的抗体とその利用法
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
ES2457538T3 (es) 2003-02-20 2014-04-28 Seattle Genetics, Inc. Conjugados de anticuerpo anti-CD70-fármaco y su uso para el tratamiento de cánder y trastornos inmunológicos
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
US8007805B2 (en) 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
WO2005058961A2 (en) 2003-12-12 2005-06-30 Amgen Inc. Antibodies specific for human galanin, and uses thereof
DK1711528T3 (da) 2003-12-23 2012-08-20 Genentech Inc Behandling af cancer med hidtil ukendte anti-il 13 monoklonale antistoffer
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
US7846438B2 (en) 2004-08-03 2010-12-07 Biogen Idec Ma Inc. Methods of promoting neurite outgrowth with soluble TAJ polypeptides
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
AR052051A1 (es) 2004-12-15 2007-02-28 Neuralab Ltd Anticuerpos ab humanizados usados en mejorar la cognicion
EP1871418B1 (de) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanisierte, anti-cd70-bindende wirkstoffe und ihre verwendung
CN102321174B (zh) 2005-05-06 2013-10-16 津莫吉尼蒂克斯公司 Il-31单克隆抗体及使用方法
EP1885393A4 (de) 2005-05-18 2011-03-02 Childrens Hosp & Res Ct Oak Verfahren und zusammensetzungen zur immunisierung gegen chlamydien-infektionen
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2007008604A2 (en) 2005-07-08 2007-01-18 Bristol-Myers Squibb Company Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
EP1920057A4 (de) 2005-08-03 2009-03-18 Grains Res & Dev Corp Polysaccharid-synthasen
PT2573114T (pt) 2005-08-10 2016-07-13 Macrogenics Inc Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
JP5905184B2 (ja) 2005-10-13 2016-04-20 ヒューマン ジノーム サイエンシーズ， インコーポレイテッドＨｕｍａｎ Ｇｅｎｏｍｅ Ｓｃｉｅｎｃｅｓ， Ｉｎｃ． 自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
EP3299027A1 (de) 2005-11-04 2018-03-28 Genentech, Inc. Verwendung von komplementweginhibitoren zur behandlung von augenkrankheiten
AU2006311661B2 (en) 2005-11-07 2011-05-26 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
DOP2006000277A (es) 2005-12-12 2007-08-31 Bayer Pharmaceuticals Corp Anticuerpos anti mn y métodos para su utilización
CA2637387A1 (en) 2006-01-18 2007-07-26 Simon Goodman Specific therapy using integrin ligands for treating cancer
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
SG10201504662WA (en) 2006-06-14 2015-07-30 Macrogenics Inc Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
WO2008019199A2 (en) 2006-06-26 2008-02-14 Macrogenics, Inc. FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
BRPI0715660B8 (pt) 2006-09-01 2021-05-25 Zymogenetics Inc anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal
EP2354254A1 (de) 2006-09-06 2011-08-10 Ortho-McNeil Pharmaceutical, Inc. Biomarker zur Überprüfung der Reaktion auf eine C-Met-Behandlung
AU2007313300A1 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
US8455622B2 (en) 2006-12-01 2013-06-04 Seattle Genetics, Inc. Variant target binding agents and uses thereof
TWI419904B (zh) 2006-12-18 2013-12-21 Genentech Inc 拮抗劑抗-ｎｏｔｃｈ３抗體及其用於預防及治療ｎｏｔｃｈ３相關疾病之用途
NZ577976A (en) 2007-01-09 2011-12-22 Biogen Idec Inc Sp35 antibodies and uses thereof
EP2441464B1 (de) 2007-01-18 2014-04-09 Merck Patent GmbH Integrin-liganden zur verwendung in der behandlung von darmkrebs
WO2008100995A1 (en) 2007-02-14 2008-08-21 Vaccinex, Inc. Humanized anti-cd100 antibodies
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
AU2008255027B2 (en) 2007-05-14 2013-10-03 Astrazeneca Ab Methods of reducing eosinophil levels
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
PT2182983E (pt) 2007-07-27 2014-09-01 Janssen Alzheimer Immunotherap Tratamento de doenças amiloidogénicas com anticorpos anti-abeta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP4053546A1 (de) 2007-12-06 2022-09-07 Genalyte, Inc. Vorrichtung und verfahren zur kennzeichnungsfreien überwachung von prozessen.
WO2009082485A1 (en) 2007-12-26 2009-07-02 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
WO2009118300A1 (en) 2008-03-25 2009-10-01 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by down-regulating frizzled-4 and/or frizzled-1
ES2458541T3 (es) 2008-05-02 2014-05-06 Seattle Genetics, Inc. Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida
EP2599793A1 (de) 2008-05-29 2013-06-05 Nuclea Biotechnologies, Inc. Anti-Phosphor-AKT-Antikörper
EP2315779A2 (de) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Antikörper gegen lingo oder fragmente davon enthaltende zusammensetzungen
WO2010027818A2 (en) 2008-08-25 2010-03-11 Dana-Farber Cancer Institute, Inc. Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
US9846126B2 (en) 2008-10-27 2017-12-19 Genalyte, Inc. Biosensors based on optical probing and sensing
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
MX345226B (es) 2008-10-29 2017-01-20 Ablynx Nv Formulaciones de moleculas de union a antigeno de dominio sencillo.
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010052288A1 (en) 2008-11-07 2010-05-14 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research Teneurin and cancer
EP2358392B1 (de) 2008-11-12 2019-01-09 MedImmune, LLC Antikörper-formulierung
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
US20110311521A1 (en) 2009-03-06 2011-12-22 Pico Caroni Novel therapy for anxiety
EP2241323A1 (de) 2009-04-14 2010-10-20 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Tenascin-W und Hirnkrebs
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
MX2011011718A (es) 2009-05-08 2012-01-27 Vaccinex Inc Anticuerpos anti-cd100 y metodos para su uso.
EP2445534A2 (de) 2009-05-25 2012-05-02 Merck Patent GmbH Kontinuierliche verabreichung von cilengitid in der krebstherapie
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
EP2292266A1 (de) 2009-08-27 2011-03-09 Novartis Forschungsstiftung, Zweigniederlassung Behandlung von Krebs durch Modulation von Copine III
WO2011036118A1 (en) 2009-09-22 2011-03-31 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Treating cancer by modulating mex-3
US9005926B2 (en) 2009-10-02 2015-04-14 Biogen Idec Ma Inc. Methods of preventing and removing trisulfide bonds
DK2486141T3 (en) 2009-10-07 2018-04-23 Macrogenics Inc FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
WO2011045352A2 (en) 2009-10-15 2011-04-21 Novartis Forschungsstiftung Spleen tyrosine kinase and brain cancers
US20120213801A1 (en) 2009-10-30 2012-08-23 Ekaterina Gresko Phosphorylated Twist1 and cancer
US20130004519A1 (en) 2010-03-05 2013-01-03 Ruth Chiquet-Ehrismann Smoci, tenascin-c and brain cancers
WO2011131611A1 (en) 2010-04-19 2011-10-27 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Modulating xrn1
US20130089538A1 (en) 2010-06-10 2013-04-11 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh Treating cancer by modulating mammalian sterile 20-like kinase 3
JP5744196B2 (ja) 2010-07-09 2015-07-08 クルセル ホランド ベー ヴェー 抗ヒト呼吸器多核体ウイルス（ｒｓｖ）抗体および使用の方法
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
CN103119062A (zh) 2010-07-16 2013-05-22 埃博灵克斯股份有限公司 修饰的单结构域抗原结合分子及其应用
CN103153328A (zh) 2010-07-16 2013-06-12 默克专利股份有限公司 肽在乳腺癌和/或骨转移灶的治疗中的用途
CN103347896B (zh) 2010-09-02 2017-06-13 瓦西尼斯公司 抗cxcl13抗体和其使用方法
US20130171159A1 (en) 2010-09-10 2013-07-04 Brian Arthur Hemmings Phosphorylated twist1 and metastasis
EP2629801B3 (de) 2010-10-22 2019-11-27 Seattle Genetics, Inc. Synergiewirkung zwischen auristatin-basierten antikörper-wirkstoffkonjugaten und hemmern des pi3k-akt-mtor-signalwegs
CA3060724A1 (en) 2010-11-05 2012-05-10 Genalyte, Inc. Optical analyte detection systems and methods of use
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
EP2640738A1 (de) 2010-11-15 2013-09-25 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Antimykotische wirkstoffe
AU2012237287B2 (en) 2011-03-30 2016-09-08 Ablynx Nv Methods of treating immune disorders with single domain antibodies against TNF-alpha
WO2012143497A2 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Neue binder-wirkstoff konjugate (adcs) und ihre verwendung
US9562252B2 (en) 2011-05-13 2017-02-07 Biogen Ma Inc. Methods of preventing and removing trisulfide bonds
CN103857699B (zh) 2011-05-24 2016-08-31 泽恩格尼亚股份有限公司 多价和单价多特异性复合物及其用途
US9181553B2 (en) 2011-06-06 2015-11-10 Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Method of treatment of breast cancers over-expressing the SHP2 signature genes
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
JP2014533247A (ja) 2011-11-01 2014-12-11 バイオノミクス インコーポレイテッド 抗体および癌を治療する方法
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
ES2899956T3 (es) 2011-11-04 2022-03-15 Zymeworks Inc Diseño de anticuerpo heterodimérico estable con mutaciones en el dominio Fc
US20140294732A1 (en) 2011-11-08 2014-10-02 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute Early diagnostic of neurodegenerative diseases
WO2013068431A1 (en) 2011-11-08 2013-05-16 Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research New treatment for neurodegenerative diseases
EP2790731A2 (de) 2011-12-14 2014-10-22 Seattle Genetics, Inc. Fgfr-binder-wirkstoff konjugate und ihre verwendung
EP2800583A1 (de) 2012-01-02 2014-11-12 Novartis AG Cdcp1 und brustkrebs
CA2864092C (en) 2012-02-10 2021-06-29 Seattle Genetics, Inc. Detection and treatment of cd30+ cancers
JP6193275B2 (ja) 2012-03-02 2017-09-06 ヴァクシネックス， インコーポレイテッド Ｂ細胞媒介炎症性疾患を治療するための方法
EP2825885B1 (de) 2012-03-12 2021-05-12 The Board of Trustees of the University of Illinois Optische analytdetektionssysteme mit magnetischer verstärkung
US20150266961A1 (en) 2012-03-29 2015-09-24 Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
AU2013258834B2 (en) 2012-05-10 2017-09-07 Zymeworks Bc Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the Fc domain
MX362497B (es) 2012-05-15 2019-01-21 Eisai Inc Un anticuerpo que se une específicamente al receptor alfa del folato y usos del mismo.
EP2855521A4 (de) 2012-05-24 2016-03-02 Mountgate Group Ltd Zusammensetzungen und verfahren in zusammenhang mit der vorbeugung und behandlung von tollwutinfektion
EP2866831A1 (de) 2012-06-29 2015-05-06 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
US20150184154A1 (en) 2012-07-05 2015-07-02 Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear New treatment for neurodegenerative diseases
WO2014006115A1 (en) 2012-07-06 2014-01-09 Novartis Ag Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
WO2014122605A1 (en) 2013-02-08 2014-08-14 Friedrich Miescher Institute For Biomedical Research Novel methods for the targeted introduction of viruses into cells
AU2013205589A1 (en) 2013-03-08 2014-09-25 Vaccinex, Inc. Anti-CXCL13 antibodies and associated epitope sequences
US9983206B2 (en) 2013-03-15 2018-05-29 The Board Of Trustees Of The University Of Illinois Methods and compositions for enhancing immunoassays
EP3424530A1 (de) 2013-03-15 2019-01-09 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und deren verwendungen
EP2981822B1 (de) 2013-05-06 2020-09-02 Scholar Rock, Inc. Zusammensetzungen und verfahren zur modulation von wachstumsfaktoren
US20160178610A1 (en) 2013-08-07 2016-06-23 Friedrich Miescher Institute For Biomedical Research New screening method for the treatment Friedreich's ataxia
EP3063317B1 (de) 2013-10-28 2020-06-03 DOTS Technology Corp. Allergennachweis
WO2015085289A1 (en) 2013-12-06 2015-06-11 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
RU2698697C2 (ru) 2013-12-23 2019-08-29 Байер Фарма Акциенгезельшафт Конъюгаты связующего (ADC) с ингибиторами KSP
AU2015240599B2 (en) 2014-04-04 2020-11-19 Bionomics, Inc. Humanized antibodies that bind LGR5
MX2016013559A (es) 2014-04-16 2017-04-27 Biocon Ltd Formulaciones de proteina estables que comprenden un exceso molar de sorbitol.
CN106413750B (zh) 2014-05-16 2022-04-29 免疫医疗有限责任公司 具有增强的治疗和诊断特性的带有改变的新生儿Fc受体结合的分子
WO2015189816A1 (en) 2014-06-13 2015-12-17 Friedrich Miescher Institute For Biomedical Research New treatment against influenza virus
US10308935B2 (en) 2014-06-23 2019-06-04 Friedrich Miescher Institute For Biomedical Research Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small RNAS
EP3157634B1 (de) 2014-06-23 2018-12-12 Bionomics, Inc. Lgr4-bindende antikörper
EP3164129A1 (de) 2014-07-01 2017-05-10 Friedrich Miescher Institute for Biomedical Research Kombination eines brafv600e-hemmers und mertk-hemmers zur melanombehandlung
US10961298B2 (en) 2014-08-21 2021-03-30 The Government Of The United States, Represented By The Secretary Of The Army Monoclonal antibodies for treatment of microbial infections
WO2016046768A1 (en) 2014-09-24 2016-03-31 Friedrich Miescher Institute For Biomedical Research Lats and breast cancer
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
EP3218005B1 (de) 2014-11-12 2023-01-04 Seagen Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
EP3220900B1 (de) 2014-11-21 2020-09-23 University of Maryland, Baltimore Systeme zur gezielten strukturspezifischen partikelabgabe
CN107635586B (zh) 2014-12-15 2021-09-24 拜耳医药股份有限公司 Ksp抑制剂与无糖基化抗-tweakr抗体的抗体-药物缀合物(adc)
KR102261618B1 (ko) 2015-03-31 2021-06-04 메디뮨 리미티드 신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
SG11201710639YA (en) 2015-06-22 2018-01-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
JP6905941B2 (ja) 2015-06-23 2021-07-21 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質（ｋｓｐ）阻害剤の抗ｂ７ｈ３抗体との抗体薬物複合体
WO2016207094A1 (de) 2015-06-23 2016-12-29 Bayer Pharma Aktiengesellschaft Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-tweakr-antikörpern
JP2018528191A (ja) 2015-08-19 2018-09-27 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー 抗体を生成する新規な方法
WO2017048902A1 (en) 2015-09-15 2017-03-23 Board Of Regents, The University Of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
US20180348224A1 (en) 2015-10-28 2018-12-06 Friedrich Miescher Institute For Biomedical Resear Ch Tenascin-w and biliary tract cancers
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
AU2017239038A1 (en) 2016-03-22 2018-10-04 Bionomics Inc Administration of an anti-LGR5 monoclonal antibody
SG11201808167VA (en) 2016-03-24 2018-10-30 Bayer Pharma AG Prodrugs of cytotoxic active agents having enzymatically cleavable groups
EP3919518A1 (de) 2016-06-15 2021-12-08 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate mit ksp-inhibitoren und anti-cd123-antikörpern
WO2018027124A1 (en) 2016-08-05 2018-02-08 Medimmune, Llc Anti-o2 antibodies and uses thereof
JP2019529418A (ja) 2016-09-16 2019-10-17 バイオノミックス リミテッド 抗体およびチェックポイント阻害剤の併用療法
SG11201903063UA (en) 2016-10-19 2019-05-30 Medimmune Llc Anti-o1 antibodies and uses thereof
US11401330B2 (en) 2016-11-17 2022-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
CN110300599A (zh) 2016-12-07 2019-10-01 艾吉纳斯公司 抗体和其使用方法
WO2018114798A1 (de) 2016-12-21 2018-06-28 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
US11433140B2 (en) 2016-12-21 2022-09-06 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (ADCs) having KSP inhibitors
IL291308B1 (en) 2016-12-21 2024-03-01 Bayer Pharma AG Drug-antibody conjugates with enzymatically cleavable groups
SG11201907889YA (en) 2017-03-03 2019-09-27 Seattle Genetics Inc Glycan-interacting compounds and methods of use
KR102637960B1 (ko) 2017-04-22 2024-02-21 이뮤노믹 쎄라퓨틱스, 인크. 개선된 lamp 구축물
JP7222915B2 (ja) 2017-05-02 2023-02-15 イミュノミック セラピューティックス， インコーポレイテッド 癌抗原を含む改善されたｌａｍｐ構築物
EP3642229A1 (de) 2017-06-21 2020-04-29 Gilead Sciences, Inc. Multispezifische antikörper, die auf hiv gp120 und cd3 abzielen
WO2019035001A1 (en) 2017-08-18 2019-02-21 Friedrich Miescher Institute For Biomedical Research NEW METHODS FOR TARGETED INTRODUCTION OF VIRUSES IN CELLS AND TISSUES
JP2020536916A (ja) 2017-10-11 2020-12-17 シアトル ジェネティクス，インコーポレイティド 抗ｃｄ３０抗体薬物複合体療法の副作用を軽減する方法
CN111936170A (zh) 2017-11-01 2020-11-13 西雅图知耐特公司 降低抗cd30抗体药物缀合物疗法的副作用的方法
WO2019094595A2 (en) 2017-11-09 2019-05-16 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
JP2021512103A (ja) 2018-01-31 2021-05-13 バイエル アクチェンゲゼルシャフトＢａｙｅｒ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｎａｍｐｔ阻害剤を含む抗体薬物複合体（ａｄｃｓ）
CN112189020A (zh) 2018-03-23 2021-01-05 西雅图基因公司 包含微管蛋白破坏剂的抗体药物缀合物用于治疗实体瘤的用途
CN112004558A (zh) 2018-04-12 2020-11-27 米迪亚制药有限责任公司 Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
SG11202009986QA (en) 2018-05-07 2020-11-27 Genmab As Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
BR112020022642A2 (pt) 2018-05-07 2021-02-17 Genmab A/S método para tratar câncer em um indivíduo, e, estojo
US20210261647A1 (en) 2018-05-15 2021-08-26 Immunomic Therapeutics, Inc Lamp constructs comprising allergens
EP3806908A1 (de) 2018-06-18 2021-04-21 Bayer Aktiengesellschaft Gegen cxcr5 gerichtete binder-wirkstoff-konjugate mit enzymatisch spaltbaren linkern und verbessertem wirkungsprofil
CA3102859A1 (en) 2018-07-03 2020-01-09 Gilead Sciences, Inc. Antibodies that target hiv gp120 and methods of use
CA3114922A1 (en) 2018-10-01 2020-04-09 Seagen Inc. Methods of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy
TW202034958A (zh) 2018-10-30 2020-10-01 丹麥商珍美寶股份有限公司 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
US11617798B2 (en) 2019-02-05 2023-04-04 Seagen Inc. Anti-CD228 antibodies and antibody-drug conjugates
US20220169706A1 (en) 2019-03-28 2022-06-02 Danisco Us Inc Engineered antibodies
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
AU2020329217A1 (en) 2019-08-12 2022-07-28 Aptevo Research And Development Llc 4-1BB and OX40 binding proteins and related compositions and methods, antibodies against 4-1BB, antibodies against OX40
CN114728046A (zh) 2019-09-25 2022-07-08 思进公司 联合抗cd30 adc、抗pd-1和化疗以治疗血液癌症
EP4038101A2 (de) 2019-10-04 2022-08-10 Seagen Inc. Anti-pd-l1-antikörper und antikörperwirkstoffkonjugate
KR20220083773A (ko) 2019-10-18 2022-06-20 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 개선된 lamp 구축물
KR20220121792A (ko) 2019-11-04 2022-09-01 씨젠 인크. 항-cd30 항체-약물 컨쥬게이트 및 hiv 감염 치료를 위한 이의 용도
TW202131954A (zh) 2019-11-07 2021-09-01 丹麥商珍美寶股份有限公司 利用鉑類劑與抗組織因子抗體－藥物共軛體之組合來治療癌症之方法
WO2021090272A1 (en) 2019-11-07 2021-05-14 Genmab A/S Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-tissue factor antibody-drug conjugate
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
CN115697400A (zh) 2020-01-31 2023-02-03 思进股份有限公司 抗cd30抗体-药物缀合物及其用于治疗非霍奇金淋巴瘤的用途
WO2021231568A1 (en) 2020-05-13 2021-11-18 Seagen Inc. Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates
IL300176A (en) 2020-08-04 2023-03-01 Seagen Inc Anti-CD228 antibodies and antibody-drug conjugates
JP2023540082A (ja) 2020-09-04 2023-09-21 ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー ＳＡＲＳ－ＣｏＶ－２ワクチン及び抗体
US20230382978A1 (en) 2020-10-15 2023-11-30 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
US20240024320A1 (en) 2020-11-17 2024-01-25 Seagen Inc. Methods of treating cancer with a combination of tucatinib and an anti-pd-1/anti-pd-l1 antibody
IL303328A (en) 2020-12-01 2023-07-01 Aptevo Res & Development Llc CD3-binding bispecific and heterodimeric antibodies to PSMA
JP2024503658A (ja) 2021-01-13 2024-01-26 メモリアル スローン－ケタリング キャンサー センター 抗ｄｌｌ３抗体－薬物コンジュゲート
US20240115720A1 (en) 2021-01-13 2024-04-11 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
WO2022251446A1 (en) 2021-05-28 2022-12-01 Alexion Pharmaceuticals, Inc. Methods for detecting cm-tma biomarkers
WO2022263357A1 (en) 2021-06-14 2022-12-22 Argenx Iip Bv Anti-il-9 antibodies and methods of use thereof
CA3221281A1 (en) 2021-06-29 2023-01-05 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
CA3225254A1 (en) 2021-07-13 2023-01-19 BioNTech SE Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
CA3234647A1 (en) 2021-10-06 2023-04-13 Genmab A/S Multispecific binding agents against pd-l1 and cd137 in combination therapy
AU2022377628A1 (en) 2021-10-29 2024-04-11 Seagen Inc. Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
WO2023083439A1 (en) 2021-11-09 2023-05-19 BioNTech SE Tlr7 agonist and combinations for cancer treatment
WO2023192436A1 (en) 2022-03-31 2023-10-05 Alexion Pharmaceuticals, Inc. Singleplex or multiplexed assay for complement markers in fresh biological samples
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
WO2023213960A1 (en) 2022-05-06 2023-11-09 Genmab A/S Methods of treating cancer with anti-tissue factor antibody-drug conjugates
WO2024054436A1 (en) 2022-09-06 2024-03-14 Alexion Pharmaceuticals, Inc. Diagnostic and prognostic biomarker profiles in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8610983D0 (en) * 1986-05-06 1986-06-11 Connaught Lab Enhancement of antigen immunogenicity
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
CA1338518C (en) * 1987-09-23 1996-08-13 Joyce M. Zarling Antibody heteroconjugates for the killing of hiv-infected cells
ES2096590T3 (es) * 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354738B2 (en) 2005-05-05 2013-01-15 Round Rock Research, Llc Structures including passivated germanium
US8592953B2 (en) 2005-05-05 2013-11-26 Round Rock Research, Llc Structures including passivated germanium

Also Published As

Publication number Publication date
AU8869491A (en) 1992-04-28
EP0553244B1 (de) 1998-12-30
EP0553244B8 (de) 2005-06-08
GR3029830T3 (en) 1999-06-30
DK0553244T3 (da) 1999-08-30
WO1992005793A1 (en) 1992-04-16
EP0553244B2 (de) 2005-04-06
EP0553244A4 (de) 1994-02-09
DK0553244T4 (da) 2005-08-01
AU667460B2 (en) 1996-03-28
JP3583420B2 (ja) 2004-11-04
DE69130709T3 (de) 2005-12-22
CA2093022A1 (en) 1992-04-06
CA2093022C (en) 2005-02-22
EP0553244A1 (de) 1993-08-04
ES2129029T5 (es) 2005-10-16
ES2129029T3 (es) 1999-06-01
JPH06502410A (ja) 1994-03-17
DE69130709T2 (de) 1999-07-22
DE69130709D1 (de) 1999-02-11

Similar Documents

Publication Publication Date Title
ATE175118T1 (de) Gezielte immunostimulierung mit bispezifischen stoffen
DE69221147D1 (de) Nicht glycosylierter Anti-CD3-IgG-Antikörper
EA200100224A1 (ru) Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
NL191212B (nl) Element voor het absorberen van kinematische energie.
NL172090C (nl) Materiaal voor gebruik bij het vormen van een asbestvrij frictie-element, alsmede frictie-element verkregen onder toepassing van het materiaal.
NL7614579A (nl) Werkwijze voor het toepassen van silanen met ver- kapte functionele groepen als hechtmiddel.
EP0597829A4 (de) Monoklonaler antikörper gegen einen neuen mit menschlichen tumoren assoziierten antigen.
NO880705L (no) Fremgangsmaate til fremstilling av makromolekylare platinaforbindelser med virkning mot kreft.
NL7603316A (nl) Werkwijze voor het dichten van breuken in uit meer dan een laag bestaande, zeer dunne membra- nen.
NO984136L (no) Humanisert kimµrt antistoffmolekyl for bruk som dianostikum, og diagnostisk preparat omfattende et slikt antistoffmolekyl
NO20001104L (no) Humaniserte antistoff mot humant gp39, sammensetninger inneholdende slike samt terapeutiske anvendelser derav
ATE171461T1 (de) Immunstimulierende monoklonale antikörper
DE69032979D1 (de) Bispezifische heteroantikörper mit zweifachen effektorfunktionen
NL7609225A (nl) Koppelingsorgaan voor veiligheidsgordels.
IT7821489V0 (it) Dispositivo per il montaggio, in particolare di cerniere per mobili.
NL7610736A (nl) Werkwijze voor het bereiden van preparaten met antigene activiteit.
ES267760Y (es) Dispositivo para el acolchado de asientos.
IT7821720A0 (it) Dispositivo di accoppiamento per cinture di sicurezza per veicoli.
NL7700970A (nl) Inrichting voor het meten van absorptie van straling in een doorsnede door een lichaam.
NL7703877A (nl) Immuno-onderzoek voor de bepaling van catechol- aminen, alsmede voor de uitvoering van een dergelijk onderzoek bruikbare antigenen en antilichamen.
NL7700916A (nl) Dragerdeeltjes voor een electrostatografisch ontwikkelaarmengsel, een daaruit verkregen elec- trostatografisch ontwikkelaarmengsel, alsmede werkwijze voor het electrostatografisch afbeel- den onder toepassing van genoemd ontwikkelaar- mengsel.
ES264798Y (es) Dispositivo de cierre para cinturones de seguridad.
NL7707660A (nl) Inrichting voor het meten van de reflektie van een vlak, spiegelend reflekterend oppervlak.
NL7812343A (nl) Legerhuis uit kunststof met inrichting voor het aanpas- sen van de legerzitting.
NL182334C (nl) Bevestigingsinrichting voor schuifdeuren, in het bijzonder voor meubels.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification

Ref document number: 0553244

Country of ref document: EP

REN Ceased due to non-payment of the annual fee